CanSino Biologics Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 2009-01-13

Employees: 1.4K

Market Cap: -

Website: http://www.cansinotech.com

Introduction: The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.

Clinical Trials

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Placebo
Biological: COVID-19 mRNA vaccine

First Posted Date: 2022-05-13

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 150

Registration Number: NCT05373472

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳
Hebei Petro China Center Hospital, Langfang, Hebei, China

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: COVID-19 mRNA vaccine
Biological: Placebo

First Posted Date: 2022-05-13

Last Posted Date: 2024-12-04

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 43

Registration Number: NCT05373485

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳
Hebei Petro China Center Hospital, Langfang, Hebei, China

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

Phase 3

Terminated

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

First Posted Date: 2021-12-23

Last Posted Date: 2023-06-15

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 91

Registration Number: NCT05169008

Locations: 🇨🇱
Hospital Carlos van Buren, Valparaíso, Región De Valparaíso, Chile
🇨🇱
Hospital Base de Osorno, Osorno, Los Lagos, Chile

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

Phase 3

Withdrawn

Conditions: COVID-19

Interventions: Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Biological: Placebo

First Posted Date: 2021-11-18

Last Posted Date: 2023-06-18

Lead Sponsor: CanSino Biologics Inc.

Registration Number: NCT05124561

A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

Not Applicable

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml

First Posted Date: 2021-06-08

Last Posted Date: 2023-02-08

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 2021

Registration Number: NCT04916886

Locations: 🇨🇳
Funing Center for Disease Control and Prevention, Yancheng, Jiangsu, China

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
Biological: Placebo for Inhalation
Biological: Placebo
Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

First Posted Date: 2021-04-12

Last Posted Date: 2023-02-08

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 840

Registration Number: NCT04840992

Locations: 🇨🇳
Jiangsu Provincal Center for Disease Control and Prevention, Nanjing, Jiangsu, China

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Phase 3

Completed

Conditions: Pneumococcal Infections
Bacterial Infections
Streptococcal Infections

Interventions: Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

First Posted Date: 2021-04-12

Last Posted Date: 2024-04-02

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 3420

Registration Number: NCT04841369

Locations: 🇨🇳
Neihuang Center for Disease Control and Prevention, Anyang, Henan, China

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo

First Posted Date: 2020-09-28

Last Posted Date: 2022-10-31

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 480

Registration Number: NCT04566770

Locations: 🇨🇳
Taixing City center for Disease Control and Prevention, Taizhou, Jiangsu, China

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Biological: Placebo

First Posted Date: 2020-08-26

Last Posted Date: 2023-06-15

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 44247

Registration Number: NCT04526990

Locations: 🇦🇷
Htal de Alta Complejidad Cuenca Alta Néstor Kirchner, Cañuelas, Buenos Aires, Argentina
🇦🇷
Inst. Médico Platense, La Plata, Buenos Aires, Argentina
🇨🇱
Clínica Andes Salud Concepción, Concepción, VII Región, Chile

and more 70 locations

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Phase 1

Conditions: COVID-19

Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Biological: Placebo

First Posted Date: 2020-05-21

Last Posted Date: 2020-07-02

Lead Sponsor: CanSino Biologics Inc.

Target Recruit Count: 696

Registration Number: NCT04398147

Locations: 🇨🇦
Canadian Center for Vaccinology, Halifax, Canada

Home Terms & Conditions Privacy Policy